Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial-Reference-Cited by-同舟云学术

Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial

Published:2017-02-14 Issue:7 Volume:17 Page:1853-1867
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

de Fijter J. W.¹,Holdaas H.²,Øyen O.³,Sanders J.-S.⁴,Sundar S.⁵,Bemelman F. J.⁶,Sommerer C.⁷,Pascual J.⁸,Avihingsanon Y.⁹,Pongskul C.¹⁰,Oppenheimer F.¹¹,Toselli L.¹²,Russ G.¹³,Wang Z.¹⁴,Lopez P.¹⁵,Kochuparampil J.¹⁵,Cruzado J. M.¹⁶,van der Giet M.¹⁷,

Affiliation:

1. Department of Nephrology; Leiden University Medical Center; Leiden the Netherlands

2. Section of Nephrology; Department of Transplant Medicine; Oslo University Hospital, Rikshospitalet; Oslo Norway

3. Section of Transplant Surgery; Department of Transplant Medicine; Oslo University Hospital, Rikshospitalet; Oslo Norway

4. Department of Nephrology; University Medical Center Groningen; University of Groningen; Groningen the Netherlands

5. Department of Nephrology; Columbia Asia Hospitals; Malleshwaram West Bangalore India

6. Department of Nephrology; Academic Medical Center; University of Amsterdam; Amsterdam the Netherlands

7. Department of Nephrology; Heidelberg University Hospital; Heidelberg Germany

8. Department of Nephrology; Hospital del Mar; Barcelona Spain

9. Faculty of Medicine; Chulalongkorn University and Excellent Center of Organ Transplantation; King Chulalongkorn Memorial Hospital; Patumwan Bangkok Thailand

10. Department of Medicine; Faculty of Medicine; Khon Kaen University; Khon Kaen Thailand

11. Department of Nephrology and Kidney Transplantation; Hospital Clínic de Barcelona; Barcelona Spain

12. Kidney, Liver and Pancreas Transplant Unit; CRAI Norte; Ministry of Health; Buenos Aires Argentina

13. University of Adelaide and Central and Northern Adelaide Renal and Transplant Service; Royal Adelaide Hospital; North Terrace Adelaide Australia

14. Biometrics and Statistical Science; Novartis Pharmaceuticals; East Hanover NJ

15. Research and Development; Novartis Pharma AG; Basel Switzerland

16. Department of Nephrology; University Hospital of Bellvitge; L'Hospitalet de Llobregat Barcelona Spain

17. Department of Nephrology; Charité - Universitätsmedizin; Berlin Germany

Funder

Novartis Pharma

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajt.14186/fullpdf

Reference31 articles.

1. Chronic renal allograft injury: Early detection, accurate diagnosis and management;Pascual;Transplant Rev,2012

2. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation;Campistol;J Am Soc Nephrol,2006

3. Effect of everolimus on skin cancers in calcineurin inhibitor-treated heart transplant recipients;Euvrard;Transpl Int,2010

4. Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials;Brennan;Am J Transplant,2011

5. Inhibition of the mTOR pathway: A possible protective role in coronary artery disease;Tarantino;Ann Med,2013

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of immunosuppressive regimens used as maintenance therapy in kidney transplantation: The CESIT study;PLOS ONE;2024-01-02

2. Kidney transplantation: the recipient;Living Donor Organ Transplantation;2024

3. Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study;Frontiers in Transplantation;2023-10-27

4. Tacrolimus—why pharmacokinetics matter in the clinic;Frontiers in Transplantation;2023-08-21

5. A comprehensive update of the metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation;Expert Opinion on Drug Metabolism & Toxicology;2023-07-03